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Interstitial lung disease (ILD) represents a severe manifestation in connective tissue diseases (CTD), with an overall incidence
of 15%, and it is still a challenge for clinicians evaluation and management. ILD is the most common manifestation of lung
involvement in Rheumatoid Arthritis (RA), observed in up to 80% of biopsies, 50% of chest Computed Tomography (CT)
and only 5% of chest radiographs. Histopatological patterns of ILD in RA may present with diﬀerent patterns, such as: usual
interstitial pneumonia, non speciﬁc interstitial pneumonia, desquamative interstitial pneumonia, organizing pneumonia, and
eosinophilic inﬁltration. The incidence of ILD in RA patients is not only related to the disease itself, many drugs may be in
fact associated with the development of pulmonary damage. Some reports suggest a causative role for TNFα inhibitors in RA-ILD
development/worsening, anyway, no deﬁnitive statement can be drawn thus data are incomplete and aﬀected by several variables.
A tight control (pulmonary function tests and/or HRCT) is mandatory in patients with preexisting ILD, but it should be also
performed in those presenting risk factors for ILD and mild respiratory symptoms. Biologic therapy should be interrupted, and,
after excluding triggering infections, corticosteroids should be administered.
1.Introduction
Connective tissue diseases (CTD) represent a heterogeneous
group of immunologicaly mediated disorders that may aﬀect
a wide variety of organs. Respiratory system is frequently
involved in some CTD such as rheumatoid arthritis (RA),
systemic sclerosis, dermatomyositis, Sj¨ ogren syndrome, and
undiﬀerentiated CTD [1]. All respiratory components may
be interested for the disease: pleura, parenchyma, airways,
and vessels. Interstitial lung disease (ILD) is an established
clinical corollary with an overall incidence of 15% in CTD;
it represents a severe manifestation that is still a challenge
for clinicians evaluation and management [2]. It has been
postulatedthataninitialtrigger(virus,trauma,etc.)activates
resident cells which produce proinﬂammatory mediators;
subsequently chemotactic cytokines guide the inﬁltration
of inﬂammatory cells which produce proﬁbrotic mediators
such as transforming growth factor B (TGF-β), platelet-
d e r i v e dg r o w t hf a c t o r ,a n dI L - 4 .T h em a t r i xc o m p o n e n t
accumulates in the extracellular compartment and disrupts
the physiologic structure causing severe functional impair-
ment [3, 4].
2.Rheumatoid Arthritisand ILD
Rheumatoid Arthritis (RA) is an inﬂammatory autoimmune
disease that aﬀects approximately 1% of the population
potentially leading to functional disability, with about 30%
of patients unable to work after 3 years of disease [5]. Nearly
50% of RA patients present extra-articular manifestations
involving skin, eye, heart, and lungs [6]. Although cardio-
vascular disease is responsible for the majority of RA-related
deaths, pulmonary complications are frequent and cause
10–20% of overall mortality [7]. ILD is the most common
manifestation of lung involvement in RA observed in up to
80% of biopsies, 50% of chest CT, and only 5% of chest
radiographs [8].2 Pulmonary Medicine
Meanageat lung disease onset is the ﬁfthor sixth decade;
some studies reported an increased prevalence in males and
longstanding RA [9, 10]. Furthermore, smokers and patients
with rheumatoid nodules, high titre of rheumatoid factor,
and antinuclear antibodies are described to be at higher risk
of developing ILD, whereas disease severity seems to be an
irrelevant factor [11]. Human leukocyte antigen B40 and
α1 antitrypsin were already described associated with ILD
development [12]. The most frequent respiratory symptoms
are progressive dyspnea and dry cough; the majority of
patients present ﬁne bibasilar crackles, and clubbing is
less common than in idiopathic pulmonary ﬁbrosis (IPF)
[11]. Histopathological patterns of ILD in RA may present
with various manifestations, sometime associated: usual
interstitial pneumonia (UIP), nonspeciﬁc interstitial pneu-
monia (NSIP), desquamative interstitial pneumonia (DIP),
organizing pneumonia, and eosinophilic inﬁltration [13].
Data on the diﬀerent prevalence of reported patterns are
contrasting.Leeetal.identiﬁedtheUIPasthemostcommon
histopathological pattern (56%) in contrast with Tansey et
al. who described the NSIP as the most prevalent [14–18]
Table 1. Imaging data have demonstrated that HRCT is more
sensitive than radiography and correlates with histopatho-
logical patterns; thus, it may allow for an early diagnosis and
should be performed in RA patients manifesting either risk
factors for ILD or minor abnormalities on chest radiographs
[17]. Recently, Zou et al. reported the most common
ﬁndings observed with HRCT in 110 RA patients: ground
glass (39.9%), honeycombing (4.5%), reticular patterns, and
consolidation (1.8%); patients with reticular patterns and
honeycombing were more likely to show the respiratory
symptoms. Other described abnormalities are architectural
distortion, pulmonary nodules, emphysema, bronchiectasis
and traction bronchiectasis, subpleural nodules, pleural
thickening, and lymph node enlargements [17, 19]. Among
routinely exams, pulmonary function tests (PFT) with dif-
fusing capacity for carbon monoxide (DLCO) are the most
sensitive; a restrictive defect is typical, but mixed ﬁndings
may be also present [20].
Despite bronchoalveolar lavage (BAL) may reveal the
presence of neutrophil alveolitis and neutrophil percentage
and has been reported to correlate with DLCO reduction,
it is not usually adopted in ILD-associated RA patients and
it is generally used to exclude complicating infections and
malignancy [21]. To adopt the correct ILD treatment in
RA patients is still a challenge. Ideally therapy should be
tailored to the histopathological pattern that remains the
best prognostic factor (i.e., the presence of active inﬂamma-
tory lesions (cellular interstitial pneumonia and lymphoid
hyperplasia) that may be reverted by an early treatment).
3. ILDand Biological Therapy
The incidence of ILD in RA patients is not only related
to the disease itself. Many drugs may be associated with
the development of pulmonary damage: nonsteroidal anti-
inﬂammatory drugs, intravenous immunoglobulin, and
synthetic DMARDs such us methotrexate, leﬂunomide,
Table 1: Histopathological patterns of RA-associated ILD.
References No. of patients
Percentage of
diﬀerent
histopathological
patterns
Lee et al., 2005 [14]1 8
UIP 10 (56%)
NSIP 6 (33%)
OP (11%)
FB 1 (6%)
Other 1 (6%)
Tansey et al., 2004 [15]1 7
NSIP 8 (47%)
FB 6 (35%)
UIP 2 (12%)
Other 1 (6%)
Bongartz et al., 2010 [16]
46 (14 of whom
based on biopsy
and/or CT)
UIP 9 (20%)
NSIP 1 (2%)
OP 3 (6,5%)
Other 15 (32.6%)
Tanaka et al., 2004 [17] 63 (17 of whom
based on biopsy)
NSIP 10 (59%)
UIP 2 (12%)
DIP 1 (6%)
Other 3 (18%)
Akira et al., 1999 [18] 29 (19 of whom
based on biopsy)
UIP 14 (74%)
OP 3 (16%)
NSIP 1 (5%)
Other 1 (5%)
UIP:usualinterstitialpneumonia;NSIP:nonspeciﬁcinterstitialpneumonia;
OP: organizing pneumonia; FB: follicular bronchiolitis; DIP: desquamative
interstitial pneumonia.
and cyclophosphamide [22]. The introduction of biologic
DMARDs has dramatically improved the course of RA by
reducing symptoms, arresting structural damage, and thus
leading to a signiﬁcant amelioration of quality of life in
these patients [23]. Anyway, these agents are not free from
side eﬀects among whom are infections, malignancies, and
demyelinating disorders [24, 25]. New onset or ILD worsen-
ing has already been reported as a possible consequence of
the three TNFα inhibitors which are the most widely used
class of biologics [26–28]( Table 2): inﬂiximab (a chimeric
IgG1k monoclonal antibody consisting of human constant
and murine variable regions), Etanercept (a dimeric fusion
proteinconsistingoftheextracellularligand-bindingportion
of human 75kDA TNF receptor linked to the Fc portion
of human IgG1), and Adalimumab (a recombinant human
IgG1 monoclonal antibody speciﬁc for human TNFα)[ 29].
In 2002, Peno-Green et al. described the ﬁrst case of ILD
in an RA patient after anti-TNFα therapy (Etanercept) [30].
By now, a total of 144 RA patients with new onset or ILD
worsening after anti-TNFα (55 inﬂiximab, 95 etanercept,
and 4 adalimumab) therapy have been reported [31]. In
2010, Dixon et al. showed higher risk of death with a higher
prevalence of ILD in the anti-TNFα group with respect to
synthetic DMARDs (2.8% versus 1.9% P = 0.006) [26].
Alvarez et al. analyzed clinical characteristics, outcomes,
and patterns of association of all reported cases of 122
patients (108 adult RA patients) developing ILD after
biologic therapy (Etanercept 58, Inﬂiximab 56, adalimumabPulmonary Medicine 3
Table 2: Number and percentage of RA patients presenting ILD under anti-TNFα treatment.
Total no. of RA patients
Patients developing ILD
References
anti-TNFα N/% Inﬂiximab N/% Etanercept N/% Adalimumab N/%
10.649 299 (2.8%) UN UN UN Dixon et al., 2010 [26]
13.894 77(0.6%) UN 77 (0.6%) UN Koike et al., 2011 [27]
5.000 25(0.5%) UN 25 (0.5%) UN Takeuchi et al., 2008 [28]
ILD: interstitial lung disease; UN: unavailable.
3, and Rituximab 5). Patients generally manifested dyspnea,
fever and cough, malaise, pleuritic pain, and haemoptysis;
the disease onset generally appeared after at least 6 months
of therapy. Diagnosis performed by HRCT (36 detailed
cases) revealed ground-glass opacities, reticular nodular,
nodular pattern, and honeycomb changes; BAL showed lym-
phocytes and macrophages. Histopathologic ﬁndings were
UIP, NSIP, organizing pneumonia, and lymphoid interstitial
pneumonia. Treatment of ILD included biologic agents
withdrawal and the use of corticosteroids, CYC, and azathio-
prine. The mortality rate was increased by age >65 years,
later onset of ILD, and the association of methotrexate and
anti-TNFα agents [32]. In contrast with these observations,
two prospective observational studies have examined the
inﬂuence of anti-TNFα therapy upon ILD. In Japan, 7091
RApatientstreatedwithetanerceptand5000patientstreated
with inﬂiximab and methotrexate were monitored for 6
months. Only 0.5% and 0.6% patients were reported to have
ILD [27, 28]( Table 2). In addition, other authors reported
good results by the use of these agents in patients with
RA-ILD. Bargagli et al. showed an improvement in lung
function evaluated by PFT DLCO and a stabilization of
HRCT abnormalities after inﬂiximab and suggests that it
may be considered as a therapeutic option for the treatment
of ILD-RA [33]. Similar results are reported by Vassallo
et al. [34]. Moreover, Antoniou et al., in 2007 evaluating
the potential eﬀectiveness of Inﬂiximab treatment for pul-
monary ﬁbrosis in three RA and one SSc patients described
that pulmonary ﬁbrosis remained stable during treatment
in terms of symptoms, PFTs, and HRCT [35]. These conﬂict-
ing results may be explained by the complex and dualistic
role of TNFα and reﬂect the contradictory data derived
by studies in vitro and in murine models.
TNFα is produced by macrophages, CD4+ and CD8+ T
cells, B cells, neutrophils, endothelial cells, and ﬁbroblast.
Several studies indicate a proﬁbrotic role for this molecule.
Transgenic mice overexpressing murine TNFα in the lung
develop a chronic lymphocytic alveolitis which severity
correlates with the expression of TNFα mRNA. Moreover,
TNFα may upregulate TGFb1 expression in the lungs via the
activation of regulated kinase pathway in ﬁbroblasts [36, 37].
On the other hand, mice KO for TNFα develop a bleomycin-
induced pulmonary ﬁbrosis that may be reverted by the
administration of TNFα [38]; TNF-α is also able to block
the synthesis of collagen production and inhibits α2 collagen
gene transcription in human dermal ﬁbroblasts [39]. Few
reports are currently available for the new biologic drugs:
rituximab (an engineered chimeric monoclonal antibody
directed against the anti-CD20 antigen found on the surface
of normal and malignant B cells) and tocilizumab (human-
ized anti-IL-6 receptor monoclonal antibody). Sixteen cases
of rituximab-induced interstitial lung disease have been
reported in haematological disorders whereas only two cases
of organizing pneumonia have been described in RA patients
[40, 41]; a clinical trial on the beneﬁt of rituximab in
RA lung disease is ongoing [42]. Kawashiri et al. recently
reported a fatal case of acute exacerbation of ILD in a RA
patient 10 months after starting tocilizumab [43]N od a t a
are currently reported about ILD onset or exacerbation for
abatacept (a dimeric fusion protein composed of CTLA4
extracellular domain and human FcIgG1, developed to block
the interactions of CD28-CD80/CD86 thus impairs T-cell
activation) in RA patients [31].
4. Conclusions
In conclusions, even if some reports seem to suggest a
c a u s a t i v er o l ef o rT N F α inhibitors in RA-ILD develop-
ment/worsening, no deﬁnitive statement can be drawn. In
additionthesedataareaﬀectedbyseveralvariables(ethnicity,
comorbidity, association with synthetic DMARDs, type of
study, etc.).Atight control(pulmonary functiontestsand/or
HRCT) is mandatory in patients with preexisting ILD, but it
should be also performed in those presenting risk factors for
ILDandmildrespiratorysymptoms.Biologictherapyshould
be interrupted, and, after excluding triggering infections,
corticosteroids should be administered. Larger controlled
studies speciﬁcally designed to assess the safety proﬁle of
anti-TNF-α and new biologics in ILD-RA patients at diﬀer-
ent steps of ILD progression are needed.
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